Risk of Major Bleeding with Ibrutinib

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Ibrutinib is an effective Bruton tyrosine kinase inhibitor for mature B-cell malignancies.
• Serious bleeding is an uncommon but serious adverse event associated with ibrutinib therapy.
• Increased use of ibrutinib in patients with comorbidities may lead to a higher rate of major bleeding.

Purpose of the Study:

• To evaluate the incidence and risk factors for major bleeding in patients treated with ibrutinib in a real-world clinical setting.
• To compare bleeding rates in clinical practice versus previously reported clinical trial data.

Main Methods:

• Retrospective analysis of 70 patients prescribed ibrutinib from January 2012 to May 2016.
• Data collected included demographics, comorbidities, bleeding events, and concurrent medications.
• Statistical analysis to identify factors associated with major bleeding.

Main Results:

• 56% of patients experienced any grade of bleeding; 19% had major bleeding (grade ≥ 3), a higher rate than previously reported.
• Anemia and elevated international normalized ratio (INR) at ibrutinib initiation were associated with increased major bleeding risk.
• Concurrent use of antiplatelet agents (70%) and/or anticoagulants (17%) was common in patients with major bleeding; combined antiplatelet and anticoagulant therapy significantly increased risk.

Conclusions:

• The rate of major bleeding with ibrutinib in a standard clinical setting is higher than previously reported.
• Patients with anemia, elevated INR, or on anticoagulant/antiplatelet therapy face significantly increased major bleeding risk.
• Careful risk-benefit assessment is crucial, especially for patients on combined antiplatelet and anticoagulation medications during ibrutinib therapy.